

Kinexus Bioinformatics Corporation Announces the Launch of a New Website and a New Proteomics Service

Redesigned Website and New KinetworksTM Proteomics Screen Available to the Public

FOR IMMEDIATE RELEASE SEPTEMBER 20, 2001

VANCOUVER, British Columbia - Dr. Steven Pelech, President and C.E.O. of Kinexus Bioinformatics Corporation, is pleased to announce the launching of a new innovative website. The website is designed to provide current information on genomics, proteomics, bioinformatics and signal transduction research with links to related sites and other scientific resources, conferences, publications, articles, abstracts and news of interest. One of the main objectives of this new website, which can be found at www.kinexus.ca, is to facilitate signal transduction research in the scientific community by making the website a major educational resource and portal for cell signalling information on the Internet.

The launch of the new website coincides with the announcement of a new service, the KinetworksTM Phosphatase Screen or KPPS-1.0, which is the third screen in a series of proteomics services offered by Kinexus. KPPS-1.0 is designed to track up to 25 protein phosphatases on a single gel and compliments the two other screens offered by Kinexus: the KinetworksTM Protein Kinase Screen which tracks 75 different protein kinases and the KinetworksTM Phospho-Site Screen, that detects over 100 kinase substrate phosphoproteins using 33 specific phospho-antibodies. These screens are designed to assist researchers in the discovery of new drug targets, new drugs, and the molecular diagnosis of disease. Future products currently in development include stress signalling and apoptosis screens. Sample preparation instructions, service agreements and order forms are available online at the new Kinexus website.

Kinexus is poised to become a major proteomics and bioinformatics company with a focus on protein kinases and other cell signalling proteins for diagnostic and therapeutic applications. Kinexus expects to emerge as a drug discovery company that uses rational, computer-aided drug design based on molecular modeling of validated, proprietary protein kinase targets.

For further information, please contact Kinexus Bioinformatics Corporation toll free at 1-866-KINEXUS or visit our website at www.kinexus.ca.